Paclitaxel Cationic Liposome (CSPC Pharmaceutical)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NamePaclitaxel Cationic Liposome (CSPC Pharmaceutical)
Drug Alias NameCSPCHA-131
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSolid tumoursCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPending
Originator CompaniesCSPC Pharmaceutical Group Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A